Pharma Equity Group A/S
CSE:PEG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pharma Equity Group A/S
Cash & Cash Equivalents
Pharma Equity Group A/S
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pharma Equity Group A/S
CSE:PEG
|
Cash & Cash Equivalents
kr498k
|
CAGR 3-Years
36%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
|
Jeudan A/S
CSE:JDAN
|
Cash & Cash Equivalents
kr137.8m
|
CAGR 3-Years
111%
|
CAGR 5-Years
4%
|
CAGR 10-Years
18%
|
|
|
Copenhagen Capital A/S
CSE:CPHCAP ST
|
Cash & Cash Equivalents
kr2.7m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
P
|
Prime Office A/S
CSE:PRIMOF
|
Cash & Cash Equivalents
kr137m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
11%
|
CAGR 10-Years
47%
|
|
|
Fast Ejendom Danmark A/S
CSE:FED
|
Cash & Cash Equivalents
kr34.8m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-13%
|
|
|
E
|
EgnsINVEST Ejendomme Tyskland A/S
CSE:EGNETY
|
Cash & Cash Equivalents
kr24.2m
|
CAGR 3-Years
54%
|
CAGR 5-Years
30%
|
CAGR 10-Years
25%
|
|
Pharma Equity Group A/S
Glance View
Pharma Equity Group A/S is a property company, which engages in the investment on real estates. The firm's purpose is, without geographical limitation, to be a holding company for companies with life science activities and to invest in shares admitted to trading on a regulated market place or multilateral trading facility and unlisted capital shares as determined by the board of directors in order to achieve long-term value growth while observing appropriate risk diversification as well as other related businesses.
See Also
What is Pharma Equity Group A/S's Cash & Cash Equivalents?
Cash & Cash Equivalents
498k
DKK
Based on the financial report for Dec 31, 2025, Pharma Equity Group A/S's Cash & Cash Equivalents amounts to 498k DKK.
What is Pharma Equity Group A/S's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
2%
Over the last year, the Cash & Cash Equivalents growth was -88%. The average annual Cash & Cash Equivalents growth rates for Pharma Equity Group A/S have been 36% over the past three years , and 2% over the past ten years .
